NEW YORK (GenomeWeb News) – Pacific Edge said on Thursday it signed an agreement with national provider network Stratose, further making Pacific Edge’s bladder cancer test available to more patients.
Stratose contracts with more than 850,000 direct and affiliate healthcare providers and offers a “medical network solution” to more than 8.6 million Americans, Pacific Edge said.
The deal expands patient access to the company’s urine-based bladder cancer test called Cxbladder, which comprises five biomarkers and identifies patients with changes in gene expression to help rule out cancer in patients with normal gene expression.
The deal with Stratose follows similar agreements the New Zealand-based cancer diagnostics firm has inked with America’s Choice Provider Network and with FedMed in recent months.
“The addition of Stratose along with FedMed and ACPN now provides network coverage to a significant pool of American people giving commercial access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test, all of which are particularly appealing to US healthcare professionals, patients, and insurers alike,” Pacific Edge CEO David Darling said in a statement.